Pfizer monovalent Omicron XBB.1.5 COVID-19 vaccine safety data – all participants

Australia’s active vaccine safety system

COVID-19 vaccines

Data on this page show the responses of individuals who received the Pfizer monovalent Omicron XBB.1.5 (age 12 years and over formulation) COVID-19 vaccine and completed an AusVaxSafety survey sent on day 3 after vaccination. These data give a profile of what to expect in the days following Pfizer XBB.1.5 COVID-19 vaccination and can assist when planning for your Pfizer XBB.1.5 COVID-19 vaccination. Note: The Pfizer XBB.1.5 COVID-19 vaccine is no longer being administered in Australia; therefore, Pfizer XBB.1.5 COVID-19 vaccine safety data below are no longer updated. AusVaxSafety has retained the display of historical Pfizer XBB.1.5 COVID-19 vaccine safety data as a reference.

AusVaxSafety’s active vaccine safety surveillance system complements the enhanced safety surveillance activities of the Therapeutic Goods Administration (TGA). Find out more about how the TGA monitors the safety of vaccines and how you can report side effects on the TGA website.

Click here to view ATAGI’s recommendations on the use of XBB.1.5 COVID-19 vaccines

Last updated March 2026

COVID-19 vaccines

New AusVaxSafety data confirms Abrysvo RSV vaccine is well tolerated during pregnancy; adverse events comparable to other maternal vaccinations

18 May 2025 | News

2025 Australian flu season: Who should get a flu shot, which vaccines are available and what to expect in the days following your vaccination

AusVaxSafety receives funding
from the Australian Government

NCIRS, Kids Research, Sydney Children’s Hospitals Network, Cnr Hawkesbury Rd & Hainsworth St, Westmead Locked Bag 4001, Westmead NSW 2145 Tel (612) 9845 1433 | Fax (612) 9845 1418 | ABN 53 188 579 090

We acknowledge that the National Centre for Immunisation Research and Surveillance (NCIRS) is on the land of the traditional owners the Aboriginal and Torres Strait Islander peoples, the First Australians, and recognise their culture, history, diversity and their deep connection to the land. Together, through research and partnership, we aim to move to a place of equity for all. NCIRS also acknowledges and pays respect to other Aboriginal and Torres Strait Islander nations from which our research, staff and community are drawn.

Our website meets the criteria for credibility and content as defined by the Global Advisory Committee on Vaccine Safety.

We acknowledge that the National Centre for Immunisation Research & Surveillance (NCIRS) is on the land of the traditional owners the Aboriginal and Torres Strait Islander peoples, the First Australians, and recognise their culture, history, diversity and their deep connection to the land. Together, through research and partnership, we aim to move to a place of equity for all. NCIRS also acknowledges and pays respect to other Aboriginal and Torres Strait Islander nations from which our research, staff and community are drawn.

Pfizer monovalent Omicron XBB.1.5 COVID-19 vaccine safety data – all participants

COVID-19 vaccines

COVID-19 vaccines

News & events

New LP.8.1 COVID-19 vaccines well tolerated, new AusVaxSafety data show

Fewer adverse events reported following NIP pneumococcal vaccine change

New AusVaxSafety data confirms Abrysvo RSV vaccine is well tolerated during pregnancy; adverse events comparable to other maternal vaccinations

2025 Australian flu season: Who should get a flu shot, which vaccines are available and what to expect in the days following your vaccination

Subscribe to our newsletter for immunisation professionals

Subscribe to our newsletter for immunisation professionals